These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 36430837)

  • 41. Proteotranscriptomic Analysis Reveals Stage Specific Changes in the Molecular Landscape of Clear-Cell Renal Cell Carcinoma.
    Neely BA; Wilkins CE; Marlow LA; Malyarenko D; Kim Y; Ignatchenko A; Sasinowska H; Sasinowski M; Nyalwidhe JO; Kislinger T; Copland JA; Drake RR
    PLoS One; 2016; 11(4):e0154074. PubMed ID: 27128972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma.
    Dong Y; Ma WM; Yang W; Hao L; Zhang SQ; Fang K; Hu CH; Zhang QJ; Shi ZD; Zhang WD; Fan T; Xia T; Han CH
    BMC Cancer; 2021 Oct; 21(1):1135. PubMed ID: 34688260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
    Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
    Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
    Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
    J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
    Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
    Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
    Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
    Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transcriptome-proteome integration of archival human renal cell carcinoma biopsies enables identification of molecular mechanisms.
    Koch E; Finne K; Eikrem Ø; Landolt L; Beisland C; Leh S; Delaleu N; Granly M; Vikse BE; Osman T; Scherer A; Marti HP
    Am J Physiol Renal Physiol; 2019 May; 316(5):F1053-F1067. PubMed ID: 30838877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Downregulation of
    Wang T; Xie F; Li YH; Liang B
    Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
    Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
    Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Update on Biomarkers in Renal Cell Carcinoma.
    Saliby RM; Saad E; Kashima S; Schoenfeld DA; Braun DA
    Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430734. PubMed ID: 38207251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
    Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
    Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma.
    Liu S; Deng X; Zhang J
    Mol Med Rep; 2019 Dec; 20(6):5075-5083. PubMed ID: 31661117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathway signature and cellular differentiation in clear cell renal cell carcinoma.
    Tun HW; Marlow LA; von Roemeling CA; Cooper SJ; Kreinest P; Wu K; Luxon BA; Sinha M; Anastasiadis PZ; Copland JA
    PLoS One; 2010 May; 5(5):e10696. PubMed ID: 20502531
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Network-based gene deletion analysis identifies candidate genes and molecular mechanism involved in clear cell renal cell carcinoma.
    Udayaraja GK; Emerson IA
    J Genet; 2021; 100():. PubMed ID: 33707362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma.
    Liu M; Pan Q; Xiao R; Yu Y; Lu W; Wang L
    Sci Rep; 2020 Jul; 10(1):12949. PubMed ID: 32737333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma.
    Cox A; Tolkach Y; Kristiansen G; Ritter M; Ellinger J
    Clin Transl Oncol; 2020 Sep; 22(9):1524-1531. PubMed ID: 31965534
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
    Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
    PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.